| All 2008 Releases |
|---|
| 11/10/08 |
Isis Reports Financial Results and Highlights for Third Quarter of 2008
|
|
| |
CARLSBAD, Calif., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the third quarter ended September 30, 2008. Isis' positive net income for the third quarters of 2008 and 2007 was $3.2 million and $20.0 million, respectively, driven primarily by signi...
|
|
| 11/06/08 |
Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., Nov 06, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research findings in the ...
|
|
| 11/06/08 |
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
|
|
| |
NEW ORLEANS and CARLSBAD, Calif., Nov 06, 2008 /PRNewswire via COMTEX News Network/ -- NEW ORLEANS and CARLSBAD, Calif., Nov. 6
/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis' cardiovascular program review of development and
late-stage research can...
|
|
| 11/04/08 |
Webcast Alert: Isis Pharmaceuticals Announces Third Quarter 2008 Financial Results Conference Call
|
|
| |
CARLSBAD, Calif., Nov 4, 2008 (GlobeNewswire via COMTEX News Network) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Third Quarter 2008 Financial Results
When: Monday, November 10, 2008, at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live ...
|
|
| 10/24/08 |
Isis' Ibis Biosciences Subsidiary Highlights the Power of the Ibis T5000 Pathogen Identification and Characterization System at the ICAAC/IDSA Meeting
|
|
| |
CARLSBAD, Calif., Oct 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that its majority-owned subsidiary, Ibis Biosciences, Inc. (Ibis), and collaborators are presenting research highlighting the ability of the Ibis T5000(TM) Biosensor System to rapidly and accurately detect and c...
|
|
| 10/03/08 |
Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
|
|
| |
CARLSBAD, Calif., Oct 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that its majority-owned subsidiary, Ibis Biosciences, Inc. (Ibis), was awarded government grants and contracts from the United States Department of Agriculture (USDA), National Institute of Justice (NIJ) and oth...
|
|
| 09/22/08 |
Webcast Alert: ATL/TV1102 Phase II Results Presented at the World Congress on Treatment and Research in Multiple Sclerosis Conference Call
|
|
| |
CARLSBAD, Calif., Sept 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Antisense Therapeutics Ltd. (ASX: ANP) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: ATL/TV1102 Phase II results presented at the World Congress on
Treatment and Research in Multiple Sclerosis
...
|
|
| 09/22/08 |
ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis
|
|
| |
MELBOURNE, Australia and CARLSBAD, Calif., Sept 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Antisense Therapeutics Ltd. (ASX: ANP) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) are pleased to advise that the results from the ATL/TV1102 Phase IIa clinical trial in patients with multiple sclerosis (MS) were presented Saturday at the Wo...
|
|
| 09/04/08 |
Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., Sep 04, 2008 (BUSINESS WIRE) -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and the companies' joint venture Regulus Therapeutics LLC, announced today that the United States Patent and Trademark Office (USPTO) has granted notices of allowance for two U.S. patent appli...
|
|
| 09/03/08 |
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 3, 2008 - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Stelios Papadopoulos, Ph.D., ...
|
|
| 08/19/08 |
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., August 19, 2008 — Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in...
|
|
| 08/13/08 |
Isis Initiates Clinical Trial of CRP Drug
|
|
| |
CARLSBAD, Calif., Aug 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including ca...
|
|
| 08/07/08 |
Isis Reports Financial Results and Highlights for Second Quarter of 2008
|
|
| |
CARLSBAD, Calif., Aug 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the second quarter ended June 30, 2008. The Company ended the quarter in the strongest financial position in its history with more than $535 million of cash and $873,000 of pro forma op...
|
|
| 08/06/08 |
Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes excepti...
|
|
| 08/04/08 |
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., Aug 04, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Garry Menzel, Ph.D., as Execu...
|
|
| 07/31/08 |
Webcast Alert: Isis Pharmaceuticals Announces Second Quarter 2008 Financial Results Conference Call
|
|
| |
CARLSBAD, Calif., Jul 31, 2008 (PrimeNewswire via COMTEX News Network) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Second Quarter 2008 Financial Results
When: Thursday, August 7, 2008, at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live...
|
|
| 07/17/08 |
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
|
|
| |
CARLSBAD, Calif., July 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Martin P. Bedigian, M.D. will join Isis on August 18, 2008 as Vice President and Chief Medical Officer. In this position, Dr. Bedigian will take the lead and be responsible for all medical aspects of Isis'...
|
|
| 07/01/08 |
Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
|
|
| |
CARLSBAD, Calif., July 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals' business update
When: Tuesday, July 1, 2008, at 10:00 a.m. ET / 7:00 a.m. PT
Via internet: Simply log onto our web site ht...
|
|
| 07/01/08 |
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
|
|
| |
CARLSBAD, Calif., July 1, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Abbott has invested an additional $20 million in Ibis Biosciences, Inc., an Isis subsidiary. The investment will allow Ibis to further develop the Ibis T5000(TM) Biosensor System, which offers a unique solu...
|
|
| 06/30/08 |
Isis Pharmaceuticals Conference Call Notice
|
|
| |
SAN DIEGO, June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals (Nasdaq: ISIS) will conduct a conference call at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, July 1, to discuss results of the TV-1102 clinical trial and the ATL / TEVA / Isis relationship.
-- ATL and TEVA announced clinical data on TV-1102 demonstrat...
|
|
| 06/24/08 |
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., Jun 24, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has been named to the annual FierceBio...
|
|
| 06/24/08 |
Genzyme and Isis Complete Licensing of Mipomersen
|
|
| |
CAMBRIDGE, Mass., and CARLSBAD, Calif., June 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced the finalization of the license and collaboration agreement for mipomersen. The collaboration provides Genzyme with exclusive worldwide rights to mipomerse...
|
|
| 06/10/08 |
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
|
|
| |
SAN FRANCISCO and CARLSBAD, Calif., June 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the presentation of new preclinical data showing that antisense drugs potently reduce levels of sodium dependent glucose transporter type 2 (SGLT2), a key component in controlling glucose re-a...
|
|
| 06/03/08 |
Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update in Conjunction With 2008 Annual Meeting of Stockholders
|
|
| |
CARLSBAD, Calif., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis Pharmaceuticals to provide a general corporate update in
conjunction with the 2008 Annual Meeting of Stockholders. The
corporate update wi...
|
|
| 06/02/08 |
Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
|
|
| |
CHICAGO and CARLSBAD, Calif., June 2, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that two of the Company's partnered oncology drugs were highlighted during the American Society of Clinical Oncology (ASCO) meeting. Data from both drugs highlighted positive activity that supports t...
|
|
| 05/27/08 |
Isis to Receive $4.6 Million From Alnylam
|
|
| |
CARLSBAD, Calif., May 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) as its portion of the upfront fees in the recently announced transaction between Takeda Pharmaceutical Company Limited ...
|
|
| 05/21/08 |
Isis Files S-3 Registration Statement
|
|
| |
CARLSBAD, Calif., May 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission relating to the registration of five million shares of Isis common stock that was purchased on February 4, 2008 ...
|
|
| 05/12/08 |
Isis Reports Financial Results and Highlights for First Quarter of 2008
|
|
| |
CARLSBAD, Calif., May 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the quarter ended March 31, 2008. The Company finished the quarter with a pro forma net operating loss (NOL) of $5.1 million, excluding compensation expense related to stock options, co...
|
|
| 05/07/08 |
Webcast Alert: Isis Pharmaceuticals Announces First Quarter 2008 Financial Results Conference Call
|
|
| |
CARLSBAD, Calif., May 7, 2008 (PrimeNewswire via COMTEX News Network) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' First Quarter 2008 Financial Results
When: Monday, May 12, 2008, at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
How: Live on the Intern...
|
|
| 05/06/08 |
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., May 06, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has obtained exclusive rights from Sta...
|
|
| 04/25/08 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
|
|
| |
CARLSBAD, Calif. and CAMBRIDGE, Mass., April 25, 2008 /PRNewswire via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced today that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate...
|
|
| 04/18/08 |
Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
|
|
| |
CARLSBAD, Calif., April 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) presented the results of two studies designed to assess the impact of lowering apoB-100 on atherosclerosis at the 2008 Annual Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Conference in Atlanta, Georgia. The data we...
|
|
| 04/17/08 |
Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance
|
|
| |
CARLSBAD, Calif. & CAMBRIDGE, Mass., Apr 17, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with Glaxo...
|
|
| 04/17/08 |
GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases
|
|
| |
LONDON & PHILADELPHIA & CARLSBAD, Calif., Apr 17, 2008 (BUSINESS WIRE) -- GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus...
|
|
| 04/14/08 |
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
|
|
| |
CARLSBAD, Calif., April 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced additional results from its ongoing Phase 2 open-label extension (OLE) study of mipomersen in patients with familial hypercholesterolemia (FH). In FH patients exposed to mipomersen for as long as 16 months, the safe...
|
|
| 04/08/08 |
Bristol-Myers Squibb Selects Isis Drug Targeting Pcsk9 as Development Candidate For Prevention and Treatment of Cardiovascular Disease
|
|
| |
CARLSBAD, Calif., April 8, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Bristol-Myers Squibb Company (NYSE: BMY) has selected a compound from the companies' collaboration as a development candidate. As a result, Isis will receive a $2 million milestone payment. The two c...
|
|
| 03/13/08 |
Isis Reports Financial Results and Highlights for Fiscal year 2007
|
|
| |
CARLSBAD, Calif., March 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2007 financial results and business highlights. The Company finished a very successful year by meeting its 2007 pro forma net operating loss (NOL) guidance with an NOL of $29.0 million. The 2007 NOL was 54...
|
|
| 03/03/08 |
Webcast Alert: Isis Pharmaceuticals Announces Financial Results and Highlights for Fiscal Year 2007 Conference Call
|
|
| |
CARLSBAD, Calif., Mar 3, 2008 (PrimeNewswire via COMTEX News Network) -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announces the following webcast:
What: Isis Pharmaceuticals' Financial Results and Highlights for Fiscal
Year 2007
When: Thursday, March 13, 2008, at 8:30 a.m. ET / 5:30 a.m. PT
Where: www.isispharm.com
...
|
|
| 02/12/08 |
Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis' Pathogen Identification Technology
|
|
| |
CARLSBAD, Calif., Feb 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that its majority-owned subsidiary, Ibis Biosciences, Inc. (Ibis), has been awarded two new Phase 2 Small Business Innovation Research (SBIR) grants and a new government contract totaling up to approximately $2....
|
|
| 02/11/08 |
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
|
|
| |
CAMBRIDGE, Mass. & CARLSBAD, Calif., Feb 11, 2008 (BUSINESS WIRE) -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today the appointment of Peter S. Linsley, Ph.D., as Chief S...
|
|
| 02/01/08 |
Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., Feb 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have received clearance under the Hart-Scott-Rodino Antitrust Improvements Act for their collaboration, which was announced on January 7, 2008. Bas...
|
|
| 01/31/08 |
Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
|
|
| |
CARLSBAD, Calif., Jan 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Abbott is investing up to $40 million in Ibis Biosciences, Inc., an Isis subsidiary. The investment will allow Ibis to further develop the Ibis T5000(TM) Biosensor System, which offers a unique solution for...
|
|
| 01/07/08 |
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
|
|
| |
CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that they have entered a major strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk ca...
|
|
| Showing 1-43 of 43 releases |
Page: 1 |
|
|
** Even though press releases remain on our site, we do not update information in individual releases to reflect subsequent developments. Content and information present in each press release was factually accurate on the issue date. **
